Literature DB >> 33549123

Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.

N A Copping1, J L Silverman2.   

Abstract

BACKGROUND: Angelman Syndrome (AS) is a rare genetic disorder characterized by impaired communication, motor and balance deficits, intellectual disabilities, recurring seizures and abnormal sleep patterns. The genetic cause of AS is neuronal-specific loss of expression of UBE3A (ubiquitin-protein ligase E6-AP), an imprinted gene. Seizure and sleep disorders are highly prevalent (> 80%) in the AS population. The present experiments were designed to identify translational, neurophysiological outcome measures in a model of AS.
METHODS: We used the exon-2 deletion mouse (Ube3a-del) on a C57BL/6J background to assess seizure, sleep and electrophysiological phenotypes. Seizure susceptibility has been reported in Ube3a-del mice with a variety of seizure induction methods. Here, we provoked seizures by a single high-dose injection of 80 mg/kg pentylenetetrazole. Novel experiments included the utilization of wireless telemetry devices to acquire global electroencephalogram (EEG) and neurophysiological data on electrographic seizures, power spectra, light-dark cycles, sleep stages and sleep spindles in Ube3a-del and WT mice.
RESULTS: Ube3a-del mice exhibited reduced seizure threshold compared to WT. EEG illustrated that Ube3a-del mice had increased epileptiform spiking activity and delta power, which corroborates findings from other laboratories and recapitulates clinical reports in AS. This is the first report to use a cortical surface-based recording by a wireless telemetry device over tethered/fixed head-mount depth recordings. Less time in both paradoxical and slow-wave sleep, longer latencies to paradoxical sleep stages and total less sleep time in Ube3a-del mice were observed compared to WT. For the first time, we detected fewer sleep spindles in the AS mouse model. LIMITATIONS: This study was limited to the exon 2 deletion mouse model, and future work will investigate the rat model of AS, containing a complete Ube3a deletion and pair EEG with behavior.
CONCLUSIONS: Our data enhance rigor and translatability as our study provides important corroboration of previous reports on epileptiform and elevated delta power. For the first time we report neurophysiological phenotypes collected via translational methodology. Furthermore, this is the first report of reduced sleep spindles, a critical marker of memory consolidation during sleep, in an AS model. Our results are useful outcomes for therapeutic testing.

Entities:  

Keywords:  Angelman Syndrome; Behavior; Genetics; Mouse models; Seizures; Sleep; Spindles; Ube3a

Year:  2021        PMID: 33549123     DOI: 10.1186/s13229-021-00416-y

Source DB:  PubMed          Journal:  Mol Autism            Impact factor:   7.509


  60 in total

1.  Sleep in children and adolescents with Angelman syndrome: association with parent sleep and stress.

Authors:  S E Goldman; T J Bichell; K Surdyka; B A Malow
Journal:  J Intellect Disabil Res       Date:  2011-11-02

2.  Angelman syndrome, a genomic imprinting disorder of the brain.

Authors:  Stormy J Chamberlain; Marc Lalande
Journal:  J Neurosci       Date:  2010-07-28       Impact factor: 6.167

3.  Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome.

Authors:  Naoko Uemura; Akiko Matsumoto; Miho Nakamura; Kazuyoshi Watanabe; Tamiko Negoro; Toshiyuki Kumagai; Kiyokuni Miura; Takashi Ohki; Seiji Mizuno; Akihisa Okumura; Kohzaburo Aso; Fumio Hayakawa; Yoko Kondo
Journal:  Brain Dev       Date:  2005-08       Impact factor: 1.961

4.  Angelman syndrome 2005: updated consensus for diagnostic criteria.

Authors:  Charles A Williams; Arthur L Beaudet; Jill Clayton-Smith; Joan H Knoll; Martin Kyllerman; Laura A Laan; R Ellen Magenis; Ann Moncla; Albert A Schinzel; Jane A Summers; Joseph Wagstaff
Journal:  Am J Med Genet A       Date:  2006-03-01       Impact factor: 2.802

5.  Revisiting epilepsy and the electroencephalogram patterns in Angelman syndrome.

Authors:  Marcio Leyser; Patricia Sola Penna; Alexandre Cardozo de Almeida; Marcio Moacyr Vasconcelos; Osvaldo J M Nascimento
Journal:  Neurol Sci       Date:  2014-01-07       Impact factor: 3.307

6.  Angelman syndrome: correlations between epilepsy phenotypes and genotypes.

Authors:  B A Minassian; T M DeLorey; R W Olsen; M Philippart; Y Bronstein; Q Zhang; R Guerrini; P Van Ness; M O Livet; A V Delgado-Escueta
Journal:  Ann Neurol       Date:  1998-04       Impact factor: 10.422

7.  UBE3A/E6-AP mutations cause Angelman syndrome.

Authors:  T Kishino; M Lalande; J Wagstaff
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

8.  Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.

Authors:  Ronald L Thibert; Kerry D Conant; Eileen K Braun; Patricia Bruno; Rana R Said; Mark P Nespeca; Elizabeth A Thiele
Journal:  Epilepsia       Date:  2009-05-12       Impact factor: 5.864

9.  Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation.

Authors:  Y H Jiang; D Armstrong; U Albrecht; C M Atkins; J L Noebels; G Eichele; J D Sweatt; A L Beaudet
Journal:  Neuron       Date:  1998-10       Impact factor: 17.173

10.  The EEG in early diagnosis of the Angelman (happy puppet) syndrome.

Authors:  S G Boyd; A Harden; M A Patton
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

View more
  7 in total

1.  Evaluation of electroencephalography biomarkers for Angelman syndrome during overnight sleep.

Authors:  Yuval Levin; Nishitha S Hosamane; Taylor E McNair; Shrujana S Kunnam; Benjamin D Philpot; Zheng Fan; Michael S Sidorov
Journal:  Autism Res       Date:  2022-03-19       Impact factor: 4.633

2.  Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells.

Authors:  Anna Adhikari; Nycole A Copping; Julie Beegle; David L Cameron; Peter Deng; Henriette O'Geen; David J Segal; Kyle D Fink; Jill L Silverman; Joseph S Anderson
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

3.  Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.

Authors:  Elizabeth L Berg; Stela P Petkova; Heather A Born; Anna Adhikari; Anne E Anderson; Jill L Silverman
Journal:  Mol Autism       Date:  2021-09-15       Impact factor: 7.509

4.  Circadian Rhythms and Sleep Are Dependent Upon Expression Levels of Key Ubiquitin Ligase Ube3a.

Authors:  Shu-Qun Shi; Carrie E Mahoney; Pavel Houdek; Wenling Zhao; Matthew P Anderson; Xinming Zhuo; Arthur Beaudet; Alena Sumova; Thomas E Scammell; Carl Hirschie Johnson
Journal:  Front Behav Neurosci       Date:  2022-03-23       Impact factor: 3.558

5.  Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency.

Authors:  Anna Adhikari; Fiona K B Buchanan; Timothy A Fenton; David L Cameron; Julian A N M Halmai; Nycole A Copping; Kyle D Fink; Jill L Silverman
Journal:  Hum Mol Genet       Date:  2022-09-10       Impact factor: 5.121

6.  Dissociating motor impairment from five-choice serial reaction time task performance in a mouse model of Angelman syndrome.

Authors:  Paola N Negrón-Moreno; David T Diep; Caleigh D Guoynes; Michael S Sidorov
Journal:  Front Behav Neurosci       Date:  2022-09-23       Impact factor: 3.617

Review 7.  Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.

Authors:  Nycole A Copping; Stephanie M McTighe; Kyle D Fink; Jill L Silverman
Journal:  Neurotherapeutics       Date:  2021-09-15       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.